

type of report	Current report
number	26/2013
company	PHARMENA

Approval of prospectus by Polish Financial Supervision Authority (KNF)

The Management Board of PHARMENA S.A. informs that on 20th May 2013 it received KNF's (Polish Financial Supervision Authority) decision approving the Company's prospectus, which was drawn up in connection with the planned public offering of series D shares with pre-emptive rights and applying for introducing to trading in Alternative Trading System on NewConnect market of 1,759,010 (one million seven hundred fifty-nine thousand and ten) pre-emptive rights to series D shares, up to 1,759,010 (one million seven hundred fifty-nine thousand and ten) allotment certificates for series D shares, and up to 1,759,010 (one million seven hundred fifty-nine thousand and ten) series D ordinary bearer shares.

The publication of the Issuer's prospectus +will take place on 22nd May 2013, on the Issuer's website (www.pharmena.com.pl) and on its Lead Manager's website, i.e. brokerage house Dom Maklerski Prospectus S.A. (www.dmprospectus.pl).

The goal of the issue of series D shares is to obtain funds for clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA in the scope of phase II ("Proof of Concept").

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board